San Antonio Breast Cancer Symposium (SABCS) 2019
Scientific Summaries
The 2019 San Antonio Breast Cancer Symposium (SABCS) takes place December 10-14 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. This resource center aims to update oncologists treating patients with breast cancer on the latest breaking research, guideline updates, and poster presentations breaking out of one of the largest breast cancer conferences in the United States.
%20(1).jpg)
Investigational Monoclonal Antibody Improves PFS in Patients With Pretreated HER2+ MBC
December 6, 2019
When combined with chemotherapy, treatment with the investigational monoclonal antibody margetuximab provoked a greater progression-free survival (PFS) benefit than trastuzumab in patients with pretreated HER2-positive metastatic breast cancer...
.jpg "Top 5 Studies Presented at SABCS 2019")
Top 5 Studies Presented at SABCS 2019
December 14, 2019The 2019 San Antonio Breast Cancer Symposium (SABCS) just wrapped up at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Leading researchers presented thousands of studies...
.jpg "HER2-Targeted Antibody–Drug Conjugate Provokes Durable Responses in Patients With Heavily Pretreated MBC")
HER2-Targeted Antibody–Drug Conjugate Provokes Durable Responses in Patients With Heavily Pretreated MBC
December 13, 2019Treatment with the HER2-targeted antibody–drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) resulted in durable objective responses when given to heavily pretreated patients with HER2-positive breast cancers...
.jpg "Oral Paclitaxel Confers Improved Response Rate, Survival Trends in Patients With Metastatic Breast Cancer")
Oral Paclitaxel Confers Improved Response Rate, Survival Trends in Patients With Metastatic Breast Cancer
December 13, 2019Treatment with an oral formulation of the chemotherapy agent paclitaxel resulted in improved response and survival outcomes when compared with the drug in its intravenous (IV) form for women with metastatic breast cancer...
.jpg "Interferon Signaling May Predict CDK4/6 Inhibitor Resistance in ER-Positive, HER2-Negative Breast Cancers")
Interferon Signaling May Predict CDK4/6 Inhibitor Resistance in ER-Positive, HER2-Negative Breast Cancers
December 12, 2019Aberrant interferon signaling may predict acquired resistance to CDK4/6 inhibitors in women with estrogen-receptor positive/HER2-negative and early breast cancers...
.jpg "Circulating Tumor DNA Testing Effectively Identifies Rare, Targetable Mutations in Patients With Breast Cancer")
Circulating Tumor DNA Testing Effectively Identifies Rare, Targetable Mutations in Patients With Breast Cancer
December 12, 2019Circulating tumor DNA testing is feasible in routine clinical practice and can be used to identify rare targetable genetic alterations in women with advanced breast cancer...
